SNY Sanofi American Depositary Shares (Each repstg one-half of one)

49.53
-0.06  -0%
Previous Close 49.59
Open 49.57
Price To book 1.82
Market Cap 124015537155
Shares 2,503,846,904
Volume 510,963
Short Ratio 2.04
Av. Daily Volume 992,268

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1Q 2018.
SAR439684 (PD-1)
Cutaneous squamous cell carcinoma
Phase 2/3 to start in additional solid tumors 2H 2017.
SAR439684 (PD-1)
Solid tumors
Phase 3 trial commenced May 2017.
SAR439684 (PD-1)
1st line Non-Small Cell Lung Cancer
Phase 2 trial suspended dosing due to fatal thrombotic event - noted September 7, 2017.
Fitusiran
Hemophilia A and B
sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
Phase 3 trial to be initiated 3Q 2017.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
Phase 3 trial initiated 2Q 2017.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
Phase 3 trial to commence 4Q 2017.
Efpeglenatide
Type 2 diabetes
Phase 3 program initiation announced July 7, 2017 with initial data due mid-late 2019. Dosing has yet to be initiated - noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event.
Fitusiran (ATLAS)
Hemophilia A and B
Phase 3 top-line data released September 20, 2017 - all endpoints met. NDA filing due by end of 2017.
Patisiran APOLLO
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 3 data due 1Q 2018.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 3 trial initiated 4Q 2016.
Sotagliflozin
Type 2 Diabetes
Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial also met primary endpoint - June 9, 2017.
Sotagliflozin
Type 1 Diabetes
Phase 3 enrollment commenced November 2016.
NeoGAA - COMET
Pompe disease
Phase 3 trial initiated December 2017.
Isatuximab
Refractory Multiple Myeloma
Phase 3 data released September 11, 2017 - primary endpoints met. 46% improvement after 52 weeks in 300 mg group. sBLA filing due by end of 2017.
Dupixent (dupilumab) - LIBERTY ASTHMA QUEST
Asthma
Phase 3 enrollment commenced 2Q 2017.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
Phase 3 trial commenced 4Q 2017.
Dupixent (dupilumab)
Nasal polyps
Pivotal Phase 2/3 trial ongoing.
REGN2810
Cutaneous squamous cell carcinoma
Pivotal Phase 2/3 trial started in July 2016
Olipudase alfa
Acid sphingomyelinase deficiency (ASMD)
Phase 3 enrolling.
REGN2810
Non-small cell lung cancer (NSCLC)
Phase 2 enrolling as of September 2017. BLA filing due 1Q 2018 pending data.
REGN2810
Basal cell carcinoma
Phase 2 trial to commence in 2017.
Dupixent (dupilumab)
Food Allergy
Phase 2 data released May 4, 2017. Phase 3 trial to be initiated 1Q 2018.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Sarilumab
Rheumatoid arthritis

Latest News

  1. Regeneron-Sanofi drug succeeds mid-stage study
  2. Sanofi/Regeneron's Dupixent Succeeds in Phase II Study
  3. Sanofi’s Consumer Healthcare Expected to Be Long-Term Driver
  4. UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study
  5. Vaccines Business Expected to Boost Sanofi’s Revenues in 2017
  6. Aimmune teams with Regeneron, Sanofi on peanut allergy drug
  7. Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis
  8. Regeneron-Sanofi throat infection drug succeeds key study
  9. Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
  10. Regeneron Advances Science To Attack Arthritis, Eye Disease, More
  11. Dupixent May Be Strong Growth Driver for Sanofi in the Future
  12. Flexion's Latest FDA Approval Reignites Takeover Chatter
  13. Specialty Segment Drives Sanofi’s Revenue Growth in 2017
  14. Sanofi and Its Peers: Analysts’ Recommendations in October
  15. Big Pharma Killed The Cancer Drug He Invented. He Raised $22 Million To Revive It
  16. A New FDA Approval Sends Small Cap Flexion Soaring
  17. Sanofi invests €170 million in new vaccine production facility in France
  18. Dow's Merck Bails On Cholesterol Drug, Prodding Shares Down
  19. Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
  20. Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis